The François Jacob Institute of Biology brings together five departments and three services
The last two years in scientific news
Finding a new treatment consists in developing a new therapeutic agent or mode of administration, but also the identification of a new therapeutic target. Next, the efficacy and safety of the new therapy must be evaluated. These are all stages in which researchers from the François Jacob Institute of Biology at the CEA (Fontenay-aux-Roses) are involved. More specifically, the researchers set up new gene, molecular or cell therapy strategies.
To develop these new therapies, scientists from the Institute’s MIRCen and STI departments combine expertise from a variety of fields: molecular biology, biochemistry, virology, physiology, motor and cognitive behavior, neurology, neurosurgery, physics, mathematics and imaging. As specialists in neurodegenerative diseases (including Alzheimer’s, Parkinson’s, Huntington’s, and multiple sclerosis) and blood diseases (beta thalassemia, sickle-cell anemia, etc.), they bring their knowledge and skills to the academic, industrial and medical worlds.
The teams at Fontenay-aux-Roses have especially been involved in several “premieres” in gene therapy, notably for the treatment of beta thalassemia and Parkinson’s disease.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.